Fig. 2: GRT-R910 samRNA induces cross-reactive binding antibodies to Spike variants of concern (VOC) that are maintained for 6 months.
Levels of SpikeWT and VOC SpikeBeta, SpikeDelta, and SpikeOmicronBA1 IgG assessed by ELISA (ELU/ml, A–C and/or MSD assay (arbitrary units/ml; D–F Box and Whisker plots (min-max; median; IQR) show IgG levels in relevant assay units. Geometric mean (GeoMean) for each treatment day is indicated. Individual values are shown for cohort 1 (open symbols), cohort 2 (closed symbols), single GRT-R910 dose (triangles), and two GRT-R910 doses (circles). A Participants in cohort 1 (n = 10) and cohort 2 (n = 7). Data from treatment day (D)1, D29, and D57. B Participants in cohort 1 (n = 4;) and cohort 2 (n = 3) who did not receive an optional second dose of GRT-R910 (total n = 7). Data from treatment days D1 (n = 7), D29 (n = 7), D57 (n = 7), and D180 (n = 4). C Participants in cohort 1 (n = 6) and cohort 2 (n = 4) who received an optional second dose of GRT-R910 (total n = 10). Data from treatment days D1 (n = 10), D29 (n = 10), D57 (n = 10), D113 (n = 10), D142 (n = 9), and D293 (n = 4). D Participants in cohort 1 (n = 4) and cohort 2 (n = 3) who did not receive an optional second dose of GRT-R910 (total n = 7). Data from treatment days D1 (n = 7), D29 (n = 7), D57 (n = 7), and D180 (n = 4). E Participants in cohort 1 (n = 6) and cohort 2 (n = 4) who received an optional second dose of GRT-R910 (total n = 10). Data from treatment days D1 (n = 10), D29 (n = 10), D57 (n = 10), D113 (n = 10), D142 (n = 9), and D293 (n = 4). F Participants in cohorts 1 and 2 with available 6-month data following one or two GRT-R910 doses. Data from treatment days D1 (n = 17), 1 month (M1) post most recent GRT-R910 dose (D29 or D142, n = 16), and 6 months (M6) post most recent GRT-R910 dose (D180 or D293, n = 8). Statistical significance as assessed by two-tailed Wilcoxon matched-pairs signed rank test is indicated (n.s.: not significant, p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001).
